☰

Chengguo Xing - Publications

Affiliations: 
Medicinal Chemistry University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Pharmaceutical Chemistry, Organic Chemistry
Tree Info Similar researchers PubMed Report error

73 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin L. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Oncogene. PMID 37020040 DOI: 10.1038/s41388-023-02679-6  0.367
2020 Sun Y, Huang J, Chen Y, Shang H, Zhang W, Yu J, He L, Xing C, Zhuang C. Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease. Bioorganic Chemistry. 103: 104172. PMID 32890991 DOI: 10.1016/J.Bioorg.2020.104172  0.313
2020 Bian T, Tagmounti A, Vulpe C, Vijendra KC, Xing C. CXL146, a novel 4H-chromene derivative, targets GRP78 to selectively eliminate multidrug resistant cancer cells. Molecular Pharmacology. PMID 32276963 DOI: 10.1124/Mol.119.118745  0.445
2019 Botello JF, Corral P, Bian T, Xing C. Kava and its Kavalactones Inhibit Norepinephrine-induced Intracellular Calcium Influx in Lung Cancer Cells. Planta Medica. PMID 31711251 DOI: 10.1055/a-1035-5183  0.314
2019 Cong H, Xu L, Wu Y, Qu Z, Bian T, Zhang W, Xing C, Zhuang C. Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives. Journal of Medicinal Chemistry. PMID 30676015 DOI: 10.1021/Acs.Jmedchem.8B01668  0.531
2019 Xing C, Wang Y, Fujioka N, Narayanapillai S, Lu J. Abstract 3333: Potential of kava in reducing lung cancer risk, tobacco use, and associated disparities Cancer Research. 79: 3333-3333. DOI: 10.1158/1538-7445.Am2019-3333  0.325
2018 Cong H, Zhao X, Castle BT, Pomeroy EJ, Zhou B, Lee J, Wang Y, Bian T, Miao Z, Zhang W, Sham YY, Odde DJ, Eckfeldt CE, Xing C, Zhuang C. An indole-chalcone inhibits multidrug-resistant cancer cell growth by targeting microtubules. Molecular Pharmaceutics. PMID 30048137 DOI: 10.1021/Acs.Molpharmaceut.8B00359  0.436
2018 Bian T, Chandagirikoppal Vijendra K, Wang Y, Meacham A, Hati S, Cogle C, Sun H, Xing C. Exploring the structure activity relationship and mechanism of a chromene scaffold (CXL series) for its selective anti-proliferative activity towards multidrug resistant cancer cells. Journal of Medicinal Chemistry. PMID 29995404 DOI: 10.1021/acs.jmedchem.8b00813  0.388
2017 Puppala M, Narayanapillai SC, Leitzman P, Sun H, Upadhyaya P, O'Sullivan MG, Hecht SS, Xing C. Pilot in vivo structure-activity relationship of dihydromethys-ticin in blocking 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced O6-methylguanine and lung tumor in A/J mice. Journal of Medicinal Chemistry. PMID 28806079 DOI: 10.1021/Acs.Jmedchem.7B00921  0.341
2017 Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z. Chalcone: A Privileged Structure in Medicinal Chemistry. Chemical Reviews. PMID 28488435 DOI: 10.1021/Acs.Chemrev.7B00020  0.308
2017 Xu X, Xu J, Shi S, Wang Q, Saxton B, Xing C, Lin Y. Abstract A06: Combination of TRAIL and Chal-24 synergistically induces autophagy-mediated apoptosis in lung cancer cells Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A06  0.483
2016 Zhou B, Yu X, Zhuang C, Villalta P, Lin Y, Lu J, Xing C. Unambiguous Identification of β-Tubulin as the Direct Cellular Target Responsible for the Cytotoxicity of Chalcone by Photoaffinity Labeling. Chemmedchem. PMID 27203512 DOI: 10.1002/Cmdc.201600150  0.306
2016 Puppala M, Zhao X, Casemore D, Zhou B, Aridoss G, Narayanapillai S, Xing C. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions. Bioorganic & Medicinal Chemistry. PMID 26867486 DOI: 10.1016/J.Bmc.2016.01.056  0.438
2016 Tang SN, Zhang J, Jiang P, Datta P, Leitzman P, O'Sullivan MG, Jiang C, Xing C, Lü J. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction. Molecular Carcinogenesis. PMID 26840761 DOI: 10.1002/Mc.22469  0.306
2016 Narayanapillai S, von Weymarn L, Carmella S, Leitzman P, Paladino J, Upadhyaya P, Hecht SS, Murphy S, Xing C. Dietary Dihydromethysticin (DHM) Increases Glucuronidation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-Butanol (NNAL) in A/J Mice, Potentially Enhancing its Detoxification. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26744252 DOI: 10.1124/Dmd.115.068387  0.334
2016 Xu J, Xu X, Shi S, Wang Q, Saxton B, Xing C, Lin Y. Abstract 3724: Combination of TRAIL and Chal-24 synergistically kills lung cancer cells through autophagy-mediated degradation of IAPs and c-FLIPL Cancer Research. 76: 3724-3724. DOI: 10.1158/1538-7445.Am2016-3724  0.41
2016 Lee JK, Autry JM, Cornea R, Bleeker N, Casemore D, Xing C, Thomas DD. Crystal Structure of the Calcium ATPase SERCA in Complex to a Novel Anti-Cancer Agent that Targets Multidrug-Resistant Leukemia Biophysical Journal. 110: 39a. DOI: 10.1016/J.Bpj.2015.11.276  0.36
2015 Lü J, Zhang J, Li L, Jiang C, Xing C. Cancer Chemoprevention with Korean Angelica: Active Compounds, Pharmacokinetics, and Human Translational Considerations. Current Pharmacology Reports. 1: 373-381. PMID 26623248 DOI: 10.1007/S40495-015-0033-Y  0.361
2015 Xu J, Xu X, Shi S, Wang Q, Saxton B, He W, Gou X, Jang JH, Nyunoya T, Wang X, Xing C, Zhang L, Lin Y. Autophagy-Mediated Degradation of IAPs and c-FLIPL Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24. Journal of Cellular Biochemistry. PMID 26448608 DOI: 10.1002/Jcb.25397  0.431
2015 Shi S, Wang Q, Xu J, Jang JH, Padilla MT, Nyunoya T, Xing C, Zhang L, Lin Y. Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis. Oncotarget. 6: 1640-51. PMID 25682199 DOI: 10.18632/Oncotarget.2746  0.502
2015 Wu W, Puppala M, Tang S, Zhang J, Xing C, Jiang C, Lu J. Abstract 2826: Equimolar vs. pharmacokinetics-guided dosing in anti-cancer efficacy assessment of precursor-product pairs: Example with pyranocoumarins from Korean Angelica Cancer Research. 75: 2826-2826. DOI: 10.1158/1538-7445.Am2015-2826  0.391
2015 Shi S, Wang Q, Xu J, Padilla MT, Nyunoya T, Xing C, Zhang L, Lin Y. Abstract 2560: The cisplatin and Chal-24 combination synergistically kills cancer cells through IAP and c-FLIP degradation, Ripoptosome formation and autophagy-mediated apoptosis Cancer Research. 75: 2560-2560. DOI: 10.1158/1538-7445.Am2015-2560  0.45
2015 Tang S, Zhang J, Wu W, Xing C, Jiang C, Lü J. Abstract 1907: Transcriptomic signatures associated with the efficacy of Angelica gigas (AGN) ethanol extract and its pyranocoumarins on two lineages of carcinogenesis in TRAMP mice Cancer Research. 75: 1907-1907. DOI: 10.1158/1538-7445.Am2015-1907  0.307
2014 Zhang J, Wang L, Zhang Y, Li L, Tang S, Xing C, Kim SH, Jiang C, Lü J. Chemopreventive effect of Korean Angelica root extract on TRAMP carcinogenesis and integrative "omic" profiling of affected neuroendocrine carcinomas. Molecular Carcinogenesis. PMID 25307620 DOI: 10.1002/Mc.22230  0.326
2014 Narayanapillai SC, Leitzman P, O'Sullivan MG, Xing C. Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice Chemical Research in Toxicology. 27: 1871-1876. PMID 25185080 DOI: 10.1021/Tx5003194  0.353
2014 Narayanapillai SC, Balbo S, Leitzman P, Grill AE, Upadhyaya P, Shaik AA, Zhou B, O'Sullivan MG, Peterson LA, Lu J, Hecht SS, Xing C. Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis. 35: 2365-72. PMID 25053626 DOI: 10.1093/Carcin/Bgu149  0.313
2014 Ding J, Mooers BH, Zhang Z, Kale J, Falcone D, McNichol J, Huang B, Zhang XC, Xing C, Andrews DW, Lin J. After embedding in membranes antiapoptotic Bcl-XL protein binds both Bcl-2 homology region 3 and helix 1 of proapoptotic Bax protein to inhibit apoptotic mitochondrial permeabilization. The Journal of Biological Chemistry. 289: 11873-96. PMID 24616095 DOI: 10.1074/Jbc.M114.552562  0.332
2014 Zhuang C, Miao Z, Wu Y, Guo Z, Li J, Yao J, Xing C, Sheng C, Zhang W. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway. Journal of Medicinal Chemistry. 57: 567-77. PMID 24428757 DOI: 10.1021/Jm401800K  0.321
2014 He W, Wang Q, Srinivasan B, Xu J, Padilla MT, Li Z, Wang X, Liu Y, Gou X, Shen HM, Xing C, Lin Y. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene. 33: 3004-13. PMID 23831571 DOI: 10.1038/Onc.2013.256  0.477
2014 Zhang J, Li L, Hale TW, Chee W, Xing C, Jiang C, Lü J. Abstract 3255: Single oral dose pharmacokinetics of cancer chemopreventive phytochemicals fromAngelica gigasNakai in men and women Cancer Research. 74: 3255-3255. DOI: 10.1158/1538-7445.Am2014-3255  0.355
2014 Tang S, Datta P, Jiang P, Leitzman P, Xing C, Jiang C, Lu J. Abstract 2133: Suppressing effect of a Kava fraction on two lineages of prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model Cancer Research. 74: 2133-2133. DOI: 10.1158/1538-7445.Am2014-2133  0.314
2013 Bleeker NP, Cornea RL, Thomas DD, Xing C. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML. Molecular Pharmaceutics. 10: 4358-66. PMID 24079514 DOI: 10.1021/Mp400458U  0.468
2013 Hermanson DL, Das SG, Li Y, Xing C. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Molecular Pharmacology. 84: 236-43. PMID 23696245 DOI: 10.1124/Mol.113.086140  0.458
2013 Das SG, Hermanson DL, Bleeker N, Lowman X, Li Y, Kelekar A, Xing C. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy. Acs Chemical Biology. 8: 327-35. PMID 23102022 DOI: 10.1021/Cb300460F  0.531
2013 Tang S, Zhang Y, Jiang P, Zhang J, Xing C, Kim S, Jiang C, Lu J. Abstract LB-184: A paradigm of carcinogenesis lineage specificities of cancer chemoprevention: KoreanAngelicaextract and its pyranocoumarins in the transgenic adenocarcinoma of mouse prostate model. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-184  0.347
2012 Zhang Y, Srinivasan B, Xing C, Lü J. A new chalcone derivative (E)-3-(4-methoxyphenyl)-2-methyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one suppresses prostate cancer involving p53-mediated cell cycle arrests and apoptosis. Anticancer Research. 32: 3689-98. PMID 22993307  0.312
2012 Warmka JK, Solberg EL, Zeliadt NA, Srinivasan B, Charlson AT, Xing C, Wattenberg EV. Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochemical and Biophysical Research Communications. 424: 488-92. PMID 22771807 DOI: 10.1016/J.Bbrc.2012.06.140  0.445
2012 Triolet J, Shaik AA, Gallaher DD, O'Sullivan MG, Xing C. Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. Nutrition and Cancer. 64: 838-46. PMID 22693990 DOI: 10.1080/01635581.2012.689917  0.321
2012 Zhang J, Li L, Jiang C, Xing C, Kim SH, Lü J. Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds. Anti-Cancer Agents in Medicinal Chemistry. 12: 1239-54. PMID 22583405 DOI: 10.2174/187152012803833071  0.415
2012 Aridoss G, Zhou B, Hermanson DL, Bleeker NP, Xing C. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment. Journal of Medicinal Chemistry. 55: 5566-81. PMID 22582991 DOI: 10.1021/Jm300515Q  0.488
2012 Zhang Y, Shaik AA, Xing C, Chai Y, Li L, Zhang J, Zhang W, Kim SH, Lü J, Jiang C. A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo. Investigational New Drugs. 30: 1820-9. PMID 21870073 DOI: 10.1007/S10637-011-9738-X  0.394
2012 Shaik AA, Tan J, Lü J, Xing C. Economically viable efficient synthesis of (±)-methysticin: A component in kava potentially responsible for its cancer chemopreventive activity Arkivoc. 2012: 137-145. DOI: 10.3998/Ark.5550190.0013.813  0.309
2012 Das S, Hermanson D, Xing C. Abstract 767: CXL017 re-sensitizes multidrug resistant leukemia cells to chemotherapy via modulating Bcl-2 family proteins and SERCA proteins Cancer Research. 72: 767-767. DOI: 10.1158/1538-7445.Am2012-767  0.526
2012 He W, Wang Q, Srinivasan B, Xu X, Chen W, Padilla MT, Gou X, Xing C, Lin Y. Abstract 2277: Autophagy-associated necroptosis contributes to cancer cell cytotoxicity induced by the chalcone compound SBC2 Cancer Research. 72: 2277-2277. DOI: 10.1158/1538-7445.Am2012-2277  0.495
2012 Xing C, Hermanson D, Das S. Abstract B39: Mechanisms of multidrug resistance in AMLs and selective targeting via small molecules Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B39  0.455
2011 Das SG, Srinivasan B, Hermanson DL, Bleeker NP, Doshi JM, Tang R, Beck WT, Xing C. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues. Journal of Medicinal Chemistry. 54: 5937-48. PMID 21780800 DOI: 10.1021/Jm200764T  0.78
2011 Zhang J, Nkhata K, Shaik AA, Wang L, Li L, Zhang Y, Higgins LA, Kim KH, Liao JD, Xing C, Kim SH, Lu J. Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention. Current Cancer Drug Targets. 11: 787-98. PMID 21762084 DOI: 10.2174/156800911796798959  0.346
2011 Johnson TE, Hermanson D, Wang L, Kassie F, Upadhyaya P, O'Sullivan MG, Hecht SS, Lu J, Xing C. Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. The American Journal of Chinese Medicine. 39: 727-42. PMID 21721153 DOI: 10.1142/S0192415X11009202  0.351
2011 Srinivasan B, Johnson TE, Xing C. Chalcone-based inhibitors against hypoxia-inducible factor 1--structure activity relationship studies. Bioorganic & Medicinal Chemistry Letters. 21: 555-7. PMID 21112783 DOI: 10.1016/J.Bmcl.2010.10.063  0.374
2011 Zhang Y, Shaik A, Chai Y, Li L, Zhang J, Zhang W, Xing C, Kim S, Lü J, Jiang C. Abstract 1848: Decursin derivatives with increased in vivo stability suppress androgen receptor signaling and prostate cancer cell growth: Structure-bioactivity relationship Cancer Research. 71: 1848-1848. DOI: 10.1158/1538-7445.Am2011-1848  0.419
2010 Chai Y, Lee HJ, Shaik AA, Nkhata K, Xing C, Zhang J, Jeong SJ, Kim SH, Lu J. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth. Breast Cancer Research : Bcr. 12: R67. PMID 20809980 DOI: 10.1186/Bcr2634  0.41
2010 Giri R, Goodell JR, Xing C, Benoit A, Kaur H, Hiasa H, Ferguson DM. Synthesis and cancer cell cytotoxicity of substituted xanthenes. Bioorganic & Medicinal Chemistry. 18: 1456-63. PMID 20129790 DOI: 10.1016/J.Bmc.2010.01.018  0.425
2010 Xing C, Johnson T, Hermanson D, Kassie F, Upadhyaya P, O'Sullivan M, Hecht S. Abstract A70: Kava as a lung cancer chemopreventive agent Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A70  0.324
2010 Chai Y, Lee H, Shaik A, NKhata K, Xing C, Kim S, Lü J. Abstract 2882: Penta-O-galloyl-beta-D-glucose induces DNA replicative S arrest and G1 arrest independent of p21Cip1, p27Kip1 and p53 in human breast cancer cells and is orally active against breast cancer xenograft Cancer Research. 70: 2882-2882. DOI: 10.1158/1538-7445.Am10-2882  0.438
2010 Zhang J, Shaik A, Nhkata K, Wang L, Kim KH, Liao JD, Xing C, Kim S, Lü J. Abstract 2879: Proteome changes in mouse prostate induced by oral administration of penta-O-galloyl-beta-D-glucose (PGG) suggest targets for cancer chemoprevention Cancer Research. 70: 2879-2879. DOI: 10.1158/1538-7445.Am10-2879  0.386
2010 Li L, Zhang J, Shaik A, Nhkata K, Xing C, Lü J. Abstract 2871: Pharmacokinetics studies of anticancer gallotannin penta-O-galloyl-beta-D-glucose (PGG) in mice Cancer Research. 70: 2871-2871. DOI: 10.1158/1538-7445.Am10-2871  0.307
2009 Srinivasan B, Johnson TE, Lad R, Xing C. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. Journal of Medicinal Chemistry. 52: 7228-35. PMID 19883086 DOI: 10.1021/Jm901278Z  0.334
2009 Das SG, Doshi JM, Tian D, Addo SN, Srinivasan B, Hermanson DL, Xing C. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues. Journal of Medicinal Chemistry. 52: 5937-49. PMID 19743858 DOI: 10.1021/Jm9005059  0.778
2009 Shaik AA, Hermanson DL, Xing C. Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity. Bioorganic & Medicinal Chemistry Letters. 19: 5732-6. PMID 19716299 DOI: 10.1016/J.Bmcl.2009.08.003  0.301
2009 Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, Al-Mousa F, Michelangeli F, Thomas DD, Lebien TW, Xing C. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Molecular Pharmacology. 76: 667-78. PMID 19561125 DOI: 10.1124/Mol.109.055830  0.419
2009 Gálvez-Peralta M, Hackbarth JS, Flatten KS, Kaufmann SH, Hiasa H, Xing C, Ferguson DM. On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic & Medicinal Chemistry Letters. 19: 4459-62. PMID 19501511 DOI: 10.1016/J.Bmcl.2009.05.037  0.471
2008 Xing C, Johnson TE, Limburg PJ. Diets, phytochemicals, and chemoprevention of tumorigenesis. Journal of Dietary Supplements. 5: 95-105. PMID 22432428 DOI: 10.1080/19390210802332877  0.323
2008 Johnson TE, Kassie F, O'Sullivan MG, Negia M, Hanson TE, Upadhyaya P, Ruvolo PP, Hecht SS, Xing C. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Cancer Prevention Research (Philadelphia, Pa.). 1: 430-8. PMID 19138990 DOI: 10.1158/1940-6207.Capr-08-0027  0.36
2008 Wang L, Sloper DT, Addo SN, Tian D, Slaton JW, Xing C. WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Research. 68: 4377-83. PMID 18519699 DOI: 10.1158/0008-5472.Can-07-6590  0.48
2008 Tian D, Das SG, Doshi JM, Peng J, Lin J, Xing C. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Letters. 259: 198-208. PMID 18037229 DOI: 10.1016/J.Canlet.2007.10.012  0.782
2008 Doshi JM, Xing C. Antagonists against anti-apoptotic Bcl-2 family proteins for cancer treatment Mini-Reviews in Organic Chemistry. 5: 171-178. DOI: 10.2174/157019308785161639  0.779
2008 Slaton JW, Wang L, Sloper D, Tian D, Addo S, Kuriyama R, Xing C. A NOVEL DUAL ANTAGONIST AGAINST BCL-2 AND MICROTUBULES THAT CAN OVERCOME DRUG RESISTANCE AND SUPPRESS GROWTH OF PROSTATE CANCER Journal of Urology. 179: 225-226. DOI: 10.1016/S0022-5347(08)60650-3  0.427
2007 Doshi JM, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Molecular Pharmaceutics. 4: 919-28. PMID 17874842 DOI: 10.1021/Mp7000846  0.761
2007 Xing C, Wang L, Tang X, Sham YY. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. Bioorganic & Medicinal Chemistry. 15: 2167-76. PMID 17227711 DOI: 10.1016/J.Bmc.2006.12.020  0.389
2006 Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. Journal of Medicinal Chemistry. 49: 7731-9. PMID 17181155 DOI: 10.1021/Jm060968R  0.774
2004 Xing C, LaPorte JR, Barbay JK, Myers AG. Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proceedings of the National Academy of Sciences of the United States of America. 101: 5862-6. PMID 15079082 DOI: 10.1073/Pnas.0307476101  0.438
2001 Skibo EB, Xing C, Dorr RT. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. Journal of Medicinal Chemistry. 44: 3545-62. PMID 11606119 DOI: 10.1021/Jm010085U  0.391
2000 Xing C, Wu P, Skibo EB, Dorr RT. Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones. Journal of Medicinal Chemistry. 43: 457-66. PMID 10669573 DOI: 10.1021/Jm990466W  0.383
Show low-probability matches.